Medicus Sciences Acquisition (Medicus Sciences Acquisition) EBIT : $-0.70 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Medicus Sciences Acquisition EBIT?

Medicus Sciences Acquisition's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2022 was $-0.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.70 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medicus Sciences Acquisition's annualized ROC % for the quarter that ended in Sep. 2022 was -0.75%. Medicus Sciences Acquisition's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -1,242.86%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medicus Sciences Acquisition's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -0.59%.

Medicus Sciences Acquisition EBIT Historical Data

The historical data trend for Medicus Sciences Acquisition's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Sciences Acquisition EBIT Chart

Medicus Sciences Acquisition Annual Data

Trend

Dec20

Dec21

EBIT

-0.62

Medicus Sciences Acquisition Quarterly Data
	Nov20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT	Get a 7-Day Free Trial			-0.17	-0.15	-0.21	-0.18	-0.17

Competitive Comparison of Medicus Sciences Acquisition's EBIT

For the Shell Companies subindustry, Medicus Sciences Acquisition's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicus Sciences Acquisition's EV-to-EBIT Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Medicus Sciences Acquisition's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medicus Sciences Acquisition's EV-to-EBIT falls into.

Medicus Sciences Acquisition EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70 Mil.

Medicus Sciences Acquisition (NAS:MSAC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medicus Sciences Acquisition's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:

	ROC % (Q: Sep. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Sep. 2022 ))	/ count )
=	-0.696 * ( 1 - 0% )	/	( (92.307	+	92.4)	/ 2 )
=	-0.696	/	92.3535
=	-0.75 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	93.393	-	0.021	-	( 1.065	-	max(0, 0.021	-	1.185	+	1.065	))
=	92.307

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	93.432	-	0.055	-	( 0.977	-	max(0, 0.055	-	1.045	+	0.977	))
=	92.4

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Medicus Sciences Acquisition's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Sep. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.696	/	( ( (0 + max(0.099, 0))	+	(0 + max(0.013, 0)) )	/	2 )
=	-0.696	/	( ( 0.099	+	0.013 )	/	2 )
=	-0.696	/	0.056
=	-1,242.86 %

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.12)	-	(0.021	+	0	+	0)
=	0.099

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.068)	-	(0.055	+	0	+	0)
=	0.013

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medicus Sciences Acquisition's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2022 )
	=	-0.703	/	118.207
	=	-0.59 %

Medicus Sciences Acquisition EBIT Related Terms

Thank you for viewing the detailed overview of Medicus Sciences Acquisition's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicus Sciences Acquisition (Medicus Sciences Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Medicus Sciences Acquisition Corp (NAS:MSAC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

152 West 57th Street, Floor 20, New York, NY, USA, 10019

Website

https://www.medicusspac.com

Medicus Sciences Acquisition Corp is a blank check company.

Executives

Eric Cheng	officer: Chief Business Officer	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Kenneth Berkovitz	director	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Christopher Kaster	director	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Ross Levine	director	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Judah Drillick	officer: Chief Financial Officer	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Jacob Gottlieb	director, 10 percent owner, officer: Executive Chairman	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Medicus Sciences Holdings Llc	10 percent owner	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Michael Castor	director, 10 percent owner, officer: Chief Executive Officer	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019

Medicus Sciences Acquisition (Medicus Sciences Acquisition) Headlines

From GuruFocus

Medicus Sciences Acquisition Corp. Announces Closing of $92,000,000 Initial Public Offering and Full Exercise of the Overallotment Option

By PRNewswire PRNewswire • 02-18-2021

Medicus Sciences Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 02-13-2023

Medicus Sciences Acquisition Corp. Announces Pricing of $80,000,000 Initial Public Offering

By PRNewswire PRNewswire • 02-16-2021